Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Anticancer efficacy of cyclodextrin-based hyperbranched polymer nanoparticles containing alpha-mangostin

Polymer Journal volume 53, pages 481–492 (2021)Cite this article

Subjects

Abstract

Alpha-mangostin (MGS) is a natural xanthone compound extracted from mangosteen pericarps. It has great potential as an excellent anticancer agent. However, the extremely low solubility of MGS in water seriously impedes its medical application. Previously, we found that cyclodextrin (CD)-based hyperbranched polymer nanoparticles (CDNPs) solubilize MGS by encapsulating it in the CD cavity and that their binding constants are 100 times higher than those of native CDs. Our findings suggested that CDNPs could be good carriers of MGS. Here, we prepared three types of CDNP from α-, β-, and ɣCDs and compared them in terms of MGS release and in vitro and in vivo anticancer efficacy. βCDNP/MGS demonstrated the greatest anticancer efficacy, while no efficacy was observed for the other CDNPs. MGS release from CDNPs/MGS can be explained by a model in which the slow and rapid modes are connected in series; before release, MGS must shift from the slow to the rapid mode. We assumed that the slow and rapid modes are related to the interior and surface CDs of CDNPs. βCDNP/MGS showed the slowest release in the slow mode. We assume that slow release in the slow mode is essential for MGS retention until the cancerous region is reached.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Phan G, Hideaki O. New compounds and potential candidates for drug discovery from medicinal plants of Vietnam. Chem Pharm Bull. 2018;66:493.

    Article  Google Scholar 

  2. Janhom P, Dharmasaroja P. Neuroprotective effects of alpha-mangostin on MPP(+)-induced apoptotic cell death in neuroblastoma SH-SY5Y cells. J Toxicol. 2015;2015:1–11. https://doi.org/10.1155/2015/919058.

    Article  Google Scholar 

  3. Jung H-A, Su B-N, Keller WJ, Mehta RG, Kinghorn AD. Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen). J Agric Food Chem. 2006;54:2077–82.

    Article  CAS  Google Scholar 

  4. Pedraza-Chaverri J, Cardenas-Rodriguez N, Orozco-Ibarra M, Perez-Rojas JM. Medicinal properties of mangosteen (Garcinia mangostana). Food Chem Toxicol. 2008;46:3227–39. https://doi.org/10.1016/j.fct.2008.07.024.

    Article  CAS  PubMed  Google Scholar 

  5. Keigo N, Norimichi N, Tsutomu A, Hideyuki Y, Yasushi O. Inhibiton of cyclooxygenase and prostaglandin E2 synthesis by ɣ-MGS, a xanthone dervative in mangosteen, in C6 rat glioma cell. Biochem Pharm. 2002;63:73–79.

    Article  Google Scholar 

  6. Akao Y, Nakagawa Y, Iinuma M, Nozawa Y. Anti-cancer effects of xanthones from pericarps of mangosteen. Inter J Mol Sci. 2008;9:355–70.

    Article  CAS  Google Scholar 

  7. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y. Deregulation of the Akt pathaway in human cancer. Curr Cancer Drug Targets. 2008;8:27–36.

    Article  CAS  Google Scholar 

  8. National Center for Biotechnology Information. PubChem Database. alpha-Mangostin, https://pubchem.ncbi.nlm.nih.gov/compound/alpha-Mangostin.

  9. Rungnim C, Phunpee S, Kunaseth M, Namuangruk S, Rungsardthong K, Rungrotmongkol T, Ruktanonchai U. Co-solvation effect on the binding mode of the alpha-mangostin/beta-cyclodextrin inclusion complex. Beilstein J Org Chem. 2015;11:2306–17. https://doi.org/10.3762/bjoc.11.251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–9. https://doi.org/10.1016/j.addr.2012.10.002.

    Article  CAS  PubMed  Google Scholar 

  11. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjugate Chem. 2010;21:797–802.

    Article  CAS  Google Scholar 

  12. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Terada Y, Kano MR, Miyazono K, Uesaka M, Nishiyama N, Kataoka K. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6:815–23. https://doi.org/10.1038/nnano.2011.166.

    Article  CAS  PubMed  Google Scholar 

  13. Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl. 2019;98:1252–76. https://doi.org/10.1016/j.msec.2019.01.066.

    Article  CAS  PubMed  Google Scholar 

  14. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel. 2000;65:271–84.

    Article  CAS  Google Scholar 

  15. Maeda H, Tsukigawa K, Fang J. A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects. Microcirculation. 2016;23:173–82. https://doi.org/10.1111/micc.12228.

    Article  CAS  PubMed  Google Scholar 

  16. Nakamura H, Etrych T, Chytil P, Ohkubo M, Fang J, Ulbrich K, Maeda H. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Rel. 2014;174:81–7. https://doi.org/10.1016/j.jconrel.2013.11.011.

    Article  CAS  Google Scholar 

  17. Nakamura H, Koziolova E, Chytil P, Etrych T, Haratake M, Maeda H. Superior penetration and cytotoxicity of HPMA copolymer conjugates of pirarubicin in tumor cell spheroid. Mol Pharm. 2019;16:3452–59. https://doi.org/10.1021/acs.molpharmaceut.9b00248.

    Article  CAS  PubMed  Google Scholar 

  18. Wathoni N, Rusdin A, Motoyama K, Joni IM, Lesmana R, Muchtaridi M. Nanoparticle drug delivery systems for alpha-Mangostin. Nanotechnol Sci Appl. 2020;13:23–36. https://doi.org/10.2147/NSA.S243017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Verma RK, Yu W, Shrivastava A, Shankar S, Srivastava RK. alpha-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice. Sci Rep. 2016;6:32743. https://doi.org/10.1038/srep32743.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yostawonkul J, Surassmo S, Namdee K, Khongkow M, Boonthum C, Pagseesing S, Saengkrit N, Ruktanonchai UR, Chatdarong K, Ponglowhapan S, Yata T. Nanocarrier-mediated delivery of alpha-mangostin for non-surgical castration of male animals. Sci Rep. 2017;7:16234–41. https://doi.org/10.1038/s41598-017-16563-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Doan THV, Lee JH, Takahashi R, Nguyen TMP, Nguyen TVA, Pham TTH, Fujii S, Sakurai K. Cyclodextrin-based nanoparticles encapsulating α-mangostin and their drug release behavior: potential carriers of α-mangostin for cancer therapy. Polym J. 2020;52:457–66. https://doi.org/10.1038/s41428-019-0296-y.

    Article  CAS  Google Scholar 

  22. Alsbaiee A, Smith BJ, Xiao L, Ling Y, Helbling DE, Dichtel WR. Rapid removal of organic micropollutants from water by a porous beta-cyclodextrin polymer. Nature 2016;529:190–94. https://doi.org/10.1038/nature16185.

    Article  CAS  PubMed  Google Scholar 

  23. Doan THV, Doan TNA, Fujii S, Sakurai K. Enhanced binding constant of cyclodextrin to alpha-mangostin in hyperbranched polymers. Chem Lett. 2020. https://doi.org/10.1246/cl.200210.

  24. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Disco. 2004;3:1023–35. https://doi.org/10.1038/nrd1576.

    Article  CAS  Google Scholar 

  25. Suzie HP, Frederik T, Nathalie CB, Jianjun C, Brendan HG, Gregory SJ, Mark ED, Marcus B, Michel J, Boudewijn J, Wim F, Annette B. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther. 2004;3:641–50. https://doi.org/10.4161/cbt.3.7.918.

    Article  Google Scholar 

  26. Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem. 2012;8:2091–9. https://doi.org/10.3762/bjoc.8.235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. D’Mello SR, Cruz CN, Chen M-L, Kapoor M, Lee SL, Tyner KM. The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017;12:523–29. https://doi.org/10.1038/nnano.2017.67.

    Article  CAS  PubMed  Google Scholar 

  28. Caputo F, Clogston J, Calzolai L, Rosslein M, Prina-Mello A. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J Control Rel. 2019;299:31–43. https://doi.org/10.1016/j.jconrel.2019.02.030.

    Article  CAS  Google Scholar 

  29. Hotarat W, Phunpee S, Rungnim C, Wolschann P, Kungwan N, Ruktanonchai U, Rungrotmongkol T, Hannongbua S. Encapsulation of alpha-mangostin and hydrophilic beta-cyclodextrins revealed by all-atom molecular dynamics simulations. J Mol Liq. 2019;288:110965–73. https://doi.org/10.1016/j.molliq.2019.110965.

    Article  CAS  Google Scholar 

  30. Lin J, Yu Y, Shigdar S, Fang DZ, Du JR, Wei MQ, Danks A, Liu K, Duan W. Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. PLoS One. 2012;7:e49277. https://doi.org/10.1371/journal.pone.0049277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Costa EC, Moreira AF, de Melo-Diogo D, Gaspar VM, Carvalho MP, Correia IJ. 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016;34:1427–41. https://doi.org/10.1016/j.biotechadv.2016.11.002.

    Article  PubMed  Google Scholar 

  32. Li L, Brunner I, Han A, Hamburger M, Kinghorn AD, Frye R, Butterweck V. Pharmacokinetics of a-mangostin in rats after intravenous and oral application. Mol Nutr Food Res. 2011;55:567–74. https://doi.org/10.1002/mnfr.201000511.

    Article  CAS  Google Scholar 

  33. Johnson JJ, Petiwala SM, Syed DN, Rasmussen JT, Adhami VM, Siddiqui IA, Kohl AM, Mukhtar H. α-Mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth. Carcinogenesis. 2012;33:413–19. https://doi.org/10.1093/carcin/bgr291.

    Article  CAS  PubMed  Google Scholar 

  34. Lee HN, Jang HY, Kim HJ, Shin SA, Choo GS, Park YS, Kim SK, Jung JY. Antitumor and apoptosis-inducing effects of alpha-mangostin extracted from the pericarp of the mangosteen fruit (Garcinia mangostana L.) in YD-15 tongue mucoepidermoid carcinoma cells. Int J Mol Med. 2016;37:939–48. https://doi.org/10.3892/ijmm.2016.2517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Shibata M, Iinuma M, Morimoto J, Kurose H, Akamatsu K, Okuno Y, Akao Y, Otsuki Y. α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation. BMC Med. 2011;9:69–87. http://www.biomedcentral.com/1741-7015/9/69.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by JSPS KAKENHI: Grant-in-Aid for Scientific Research (Grant No. 19K15394), Grant-in-Aid for Scientific Research A (20H00668), and Grant-in-Aid for Challenging Exploratory Research (20K20449).

Author information

Authors and Affiliations

  1. Department of Chemistry and Biochemistry, University of Kitakyushu, 1-1 Hibikino, Kitakyushu, Fukuoka, 808-0135, Japan

    Van T. H. Doan, Shin Takano, Ngoc Anh T. Doan, Koji Nakazawa, Shota Fujii & Kazuo Sakurai

  2. Institute of Biotechnology, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet Road, Cau Giay District, Hanoi, Vietnam

    Phuong T. M. Nguyen

  3. Key Laboratory of Enzyme and Protein Technology, VNU University of Science, Vietnam National University, 334 Nguyen Trai Street, Thanh Xuan District, Hanoi, Vietnam

    Van Anh T. Nguyen & Huong T. T. Pham

Authors
  1. Van T. H. Doan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shin Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ngoc Anh T. Doan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Phuong T. M. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Van Anh T. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huong T. T. Pham
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Koji Nakazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shota Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuo Sakurai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Shota Fujii or Kazuo Sakurai.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doan, V.T.H., Takano, S., Doan, N.A.T. et al. Anticancer efficacy of cyclodextrin-based hyperbranched polymer nanoparticles containing alpha-mangostin. Polym J 53, 481–492 (2021). https://doi.org/10.1038/s41428-020-00441-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41428-020-00441-3

This article is cited by

Search

Advanced search

Quick links